Antiviral treatment of hepatitis C

BMJ (Online)

Volumn 349, Issue , 2014, Pages

  Feeney, Eoin R ^a   Chung, Raymond T ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABT 450; ANTIVIRUS AGENT; ASUNAPREVIR; BOCEPREVIR; DACLATASVIR; DANOPREVIR; DASABUVIR; FALDAPREVIR; INTERFERON; INTERFERON LAMBDA 4; INTERLEUKIN 28B; MK 5172; NS3 PROTEASE INHIBITOR; NS5A INHIBITOR; NS5B INHIBITOR; OMBITASVIR; PEGINTERFERON ALPHA; PEGINTERFERON PLUS RIBAVIRIN; PLACEBO; PROTEIN INHIBITOR; PROTEINASE INHIBITOR; RECOMBINANT INTERFERON; RIBAVIRIN; RITONAVIR; SIMEPREVIR; SOFOSBUVIR; TELAPREVIR; UNCLASSIFIED DRUG; UNINDEXED DRUG; VANIPREVIR; VIRUS RNA;

ANEMIA; ANTIVIRAL ACTIVITY; ANTIVIRAL RESISTANCE; ANTIVIRAL THERAPY; ANUS PRURITUS; CLINICAL TRIAL (TOPIC); DISEASE COURSE; DRUG EFFICACY; DYSGEUSIA; GASTROINTESTINAL SYMPTOM; GENE; GENETIC POLYMORPHISM; GENOTYPE; HEALTH CARE COST; HEALTH CARE PLANNING; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; IFNL3 GENE; IFNL4 GENE; IMMUNOMODULATION; INCIDENCE; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; MIXED INFECTION; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRACTICE GUIDELINE; PREVALENCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; REVIEW; TREATMENT DURATION; TREATMENT RESPONSE; VIRUS LOAD; VIRUS STRAIN; VIRUS TRANSMISSION; VIRUS VIRULENCE;

EID: 84903975871     PISSN: None     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.g3308     Document Type: Review

References (90)

1. Choo QL, Kuo G, Weiner AJ, Overby LR, Bradley DW, Houghton M. Isolation of a cDNA clone derived from a blood-borne non- A, non-B viral hepatitis genome. Science 1989;244:359-62. (Pubitemid 19117877)
2. WHO. Hepatitis C. 2014. www.who.int/mediacentre/factsheets/fs164/en/.
3. Mohd Hanafiah K, Groeger J, Flaxman AD, Wiersma ST. Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence. Hepatology 2013;57:1333-42.
4. Holmberg SD, Spradling PR, Moorman AC, Denniston MM. Hepatitis C in the United States. N Engl J Med 2013;367:1859-61.
5. Marcellin P. Hepatitis C: The clinical spectrum of the disease. J Hepatol 1999;31(suppl 1):9-16. (Pubitemid 30002685)
6. Zoulim F, Chevallier M, Maynard M, Trepo C. Clinical consequences of hepatitis C virus infection. Rev Med Virol 2003;13:57-68. (Pubitemid 36125505)
7. Dorner M, Horwitz JA, Donovan BM, Labitt RN, Budell WC, Friling T, et al. Completion of the entire hepatitis C virus life cycle in genetically humanized mice. Nature 2013;501:237-41.
8. Chevaliez S, Pawlotsky J-M. HCV genome and life cycle. In: Tan S-L, ed. Hepatitis C viruses: genomes and molecular biology Horizon Bioscience, 2006.
9. Smith DB, Bukh J, Kuiken C, Muerhoff AS, Rice CM, Stapleton JT, et al. Expanded classification of hepatitis C virus into 7 genotypes and 67 subtypes: updated criteria and assignment web resource. Hepatology 2014;59:318-27.
10. Lehmann M, Meyer MF, Monazahian M, Tillmann HL, Manns MP, Wedemeyer H. High rate of spontaneous clearance of acute hepatitis C virus genotype 3 infection. J Med Virol 2004;73:387-91. (Pubitemid 38685745)
11. Rubbia-Brandt L, Fabris P, Paganin S, Leandro G, Male PJ, Giostra E, et al. Steatosis affects chronic hepatitis C progression in a genotype specific way. Gut 2004;53:406-12. (Pubitemid 38241339)
12. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: A randomised trial. Lancet 2001;358:958-65. (Pubitemid 32913521)
13. Berger KL, Triki I, Cartier M, Marquis M, Massariol MJ, Bocher WO, et al. Baseline hepatitis C virus (HCV) NS3 polymorphisms and their impact on treatment response in clinical studies of the HCV NS3 protease inhibitor faldaprevir. Antimicrob Agents Chemother 2014;58:698-705.
14. Paolucci S, Fiorina L, Mariani B, Gulminetti R, Novati S, Barbarini G, et al. Naturally occurring resistance mutations to inhibitors of HCV NS5A region and NS5B polymerase in DAA treatment-naive patients. Virol J 2013;10:355.
15. Ge D, Fellay J, Thompson AJ, Simon JS, Shianna KV, Urban TJ, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009;461:399-401.
16. Tanaka Y, Nishida N, Sugiyama M, Kurosaki M, Matsuura K, Sakamoto N, et al. Genome-wide association of IL28B with response to pegylated interferon- Alpha and ribavirin therapy for chronic hepatitis C. Nat Genet 2009;41:1105-9.
17. Prokunina-Olsson L, Muchmore B, Tang W, Pfeiffer RM, Park H, Dickensheets H, et al. A variant upstream of IFNL3 (IL28B) creating a new interferon gene IFNL4 is associated with impaired clearance of hepatitis C virus. Nat Genet 2013;45:164-71.
18. Akuta N, Suzuki F, Hirakawa M, Kawamura Y, Yatsuji H, Sezaki H, et al. Amino acid substitution in hepatitis C virus core region and genetic variation near the interleukin 28B gene predict viral response to telaprevir with peginterferon and ribavirin. Hepatology 2010;52:421-9.
19. Pol S, Aerssens J, Zeuzem S, Andreone P, Lawitz EJ, Roberts S, et al. Limited impact of IL28B genotype on response rates in telaprevir- Treated patients with prior treatment failure. J Hepatol 2013;58:883-9.
20. Lawitz E, Poordad FF, Pang PS, Hyland RH, Ding X, Mo H, et al. Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): An open-label, randomised, phase 2 trial. Lancet 2014;383:515-23.
21. Swain MG, Lai M-Y, Shiffman ML, Cooksley WGE, Zeuzem S, Dieterich DT, et al. A sustained virologic response is durable in patients with chronic hepatitis C treated with peginterferon alfa-2a and ribavirin. Gastroenterology 2010;139:1593-601.
22. Bruno S, Stroffolini T, Colombo M, Bollani S, Benvegnù L, Mazzella G, et al. Sustained virological response to interferon- Alpha is associated with improved outcome in HCV-related cirrhosis: A retrospective study. Hepatol (Baltimore) 2007;45:579-87. (Pubitemid 46453759)
23. Chen J, Florian J, Carter W, Fleischer RD, Hammerstrom TS, Jadhav PR, et al. Earlier sustained virologic response end points for regulatory approval and dose selection of hepatitis C therapies. Gastroenterology 2013;144:1450- 55.e2.
24. Tilg H. New insights into the mechanisms of interferon alfa: An immunoregulatory and anti-inflammatory cytokine. Gastroenterology 1997;112:1017-21. (Pubitemid 27113829)
25. Schoggins JW, Wilson SJ, Panis M, Murphy MY, Jones CT, Bieniasz P, et al. A diverse range of gene products are effectors of the type I interferon antiviral response. Nature 2011;472:481-5.
26. Feld JJ, Hoofnagle JH. Mechanism of action of interferon and ribavirin in treatment of hepatitis C. Nature 2005;436:967-72. (Pubitemid 41191673)
27. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: A randomised trial. Lancet 2001;358:958-65. (Pubitemid 32913521)
28. Mangia A, Santoro R, Minerva N, Ricci GL, Caretta V, Perscio M, et al. Peginterferon alfa-2b and ribavirin for 12 vs 24 weeks in HCV genotype 2 or 3. N Engl J Med 2005;352:2609-17. (Pubitemid 41007847)
29. McHutchison JG, Lawitz EJ, Shiffman ML, Muir AJ, Galler GW, McCone J, et al. Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N Engl J Med 2009;361:580-93.
30. Lindenbach BD, Meuleman P, Ploss A, Vanwolleghem T, Syder AJ, McKeating JA, et al. Cell culture-grown hepatitis C virus is infectious in vivo and can be recultured in vitro. Proc Natl Acad Sci U S A 2006;103:3805-9. (Pubitemid 43376636)
31. Halfon P, Locarnini S. Hepatitis C virus resistance to protease inhibitors. J Hepatol 2011;55:192-206.
32. Fried MW, Buti M, Dore GJ, Flisiak R, Ferenci P, Jacobson I, et al. Once-daily simeprevir (TMC435) with pegylated interferon and ribavirin in treatment-naive genotype 1 hepatitis C: The randomized PILLAR study. Hepatology 2013;58:1918-29.
33. Wang C, Huang H, Valera L, Sun JH, O'Boyle DR 2nd, Nower PT, et al. Hepatitis C virus RNA elimination and development of resistance in replicon cells treated with BMS-790052. Antimicrob Agents Chemother 2012;56:1350-8.
34. Lam AM, Espiritu C, Bansal S, Micolochick Steuer HM, Niu C, Zennou V, et al. Genotype and subtype profiling of PSI-7977 as a nucleotide inhibitor of hepatitis C virus. Antimicrob Agents Chemother 2012;56:3359-68.
35. Jacobson IM, McHutchison JG, Dusheiko G, Di Bisceglie AM, Reddy KR, Bzowej NH, et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011;364:2405-16.
36. Zeuzem S, Andreone P, Pol S, Lawitz E, Diago M, Roberts S, et al. Telaprevir for retreatment of HCV infection. N Engl J Med 2011;364:2417-28.
37. Poordad F, McCone J Jr, Bacon BR, Bruno S, Manns MP, Sulkowski MS, et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011;364:1195-206.
38. Bacon BR, Gordon SC, Lawitz E, Marcellin P, Vierling JM, Zeuzem S, et al. Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med 2011;364:1207-17.
39. Jacobson IM, Dore GJ, Foster GR. Simeprevir (TMC435) with peginterferon/ribavirin for treatment of chronic HCV genotype 1 infection in treatment-naïve patients: efficacy in difficult- To- Treat patient sub-populations in the QUEST 1 and 2 phase III trials. Abstract 1122. 64th Annual Meeting of the American Association for the Study of Liver Diseases, 1-5 November 2013, Washington, DC.
40. Zeuzem S, Berg T, Gane E, Ferenci P, Foster GR, Fried MW, et al. Simeprevir increases rate of sustained virologic response among treatment-experienced patients with HCV genotype-1 infection: A phase IIb trial. Gastroeneterology 2014;146:430-41.
41. Lawitz E, Forns X, Zeuzem S, Gane E, Bronowicki J-P, Andreone P, et al. Simeprevir (TMC435) with peginterferon/ribavirin for treatment of chronic HCV genotype 1 infection in patients who relapsed after previous interferon-based therapy: results from PROMISE, a phase III trial. Gastroenterology 2013;144:S51.
42. Jensen D, Asselah T, Dietrich D. A pooled analysis of two randomized, double-blind, placebo-controlled phase III trials (STARTVerso1 and 2) of faldaprevir plus pegylated interferon a-2a and ribavirin in treatment-naïve patients with chronic hepatitis C genotype-1 infection. Abstract 1088. 64th Annual Meeting of the American Association for the Study of Liver Diseases, 1-5 November 2013, Washington, DC.
43. Jacobson I, Asselah T, Ferenci P, Foster G, Jensen D, Negro F. STARTVerso3: A randomized, double-blind, placebo-controlled phase III trial of faldaprevir in combination with pegylated interferon alfa-2a and ribavirin in treatment-experienced patients with chronic hepatitis C genotype-1 infection. Abstract 1100. 64th Annual Meeting of the American Association for the Study of Liver Diseases, 1-5 November 2013, Washington, DC.
44. Marcellin P, Cooper C, Balart L, Larrey D, Box T, Yoshida E, et al. Randomized controlled trial of danoprevir plus peginterferon alfa-2a and ribavirin in treatment-naive patients with hepatitis C virus genotype 1 infection. Gastroenterology 2013;145:790-800e3.
45. Bronowicki JP, Pol S, Thuluvath PJ, Larrey D, Martorell CT, Rustgi VK, et al. Randomized study of asunaprevir plus pegylated interferon- Alpha and ribavirin for previously untreated genotype 1 chronic hepatitis C. Antiviral Ther 2013;18:885-93.
46. Manns MP, Gane E, Rodriguez- Torres M, Stoehr A, Yeh CT, Marcellin P, et al. Vaniprevir with pegylated interferon alpha-2a and ribavirin in treatment-naive patients with chronic hepatitis C: A randomized phase II study. Hepatology 2012;56:884-93.
47. Hezode C, Hirschfield GM, Ghesquiere W, Sievert W, Rodriguez- Torres M, Shafran SD, et al. Daclatasvir, an NS5A replication complex inhibitor, combined with peginterferon alfa-2a and ribavirin in treatment-naive HCV-genotype 1 or 4 subjects: phase 2b COMMAND-1 SVR12 results. Hepatology 2012;56:553A- 4A.
48. Dore G, Lawitz E, H'ezode C, Shafran S, Ramji A, Tatum H, et al. Daclatasvir combined with peginterferon alfa-2a and ribavirin for 12 or 16 weeks in patients with HCV genotype 2 or 3 infection: COMMAND GT2/3 study. J Hepatol 2013;58:S570-1.
49. Lawitz E, Lalezari JP, Hassanein T, Kowdley KV, Poordad FF, Sheikh AM, et al. Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: A randomised, double-blind, phase 2 trial. Lancet Infect Dis 2013;13:401-8.
50. Kowdley KV, Lawitz E, Crespo I, Hassanein T, Davis MN, DeMicco M, et al. Sofosbuvir with pegylated interferon alfa-2a and ribavirin for treatment-naive patients with hepatitis C genotype-1 infection (ATOMIC): An open-label, randomised, multicentre phase 2 trial. Lancet 2013;381:2100-7.
51. Lawitz E, Mangia A, Wyles D, Rodriguez- Torres M, Hassanein T, Gordon SC, et al. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med 2013;368:1878-87.
52. Lawitz E, Poordad F, Brainard D. Sofosbuvir in combination with PegIFN and ribavirin for 12 weeks provides high SVR rates in HCV-infected genotype 2 or 3 treatment experienced patients with and without compensated cirrhosis: results from the LONESTAR-2 study. Abstract LB-4. 64th Annual Meeting of the American Association for the Study of Liver Diseases. Washington, DC, 1-5 November 2013.
53. Jacobson IM, Gordon SC, Kowdley KV, Yoshida EM, Rodriguez- Torres M, Sulkowski MS, et al. Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. N Engl J Med 2013;368:1867-77.
54. Zeuzem S, Dusheiko G, Salupere R, Mangia A, Flisiak R, Hyland RH, et al. Sofosbuvir and ribavirin in HCV genotypes 2 and 3. N Engl J Med 2014;370:1993-2001.
55. Osinusi A, Meissner EG, Lee YJ, Bon D, Heytens L, Nelson A, et al. Sofosbuvir and ribavirin for hepatitis C genotype 1 in patients with unfavorable treatment characteristics: A randomized clinical trial. JAMA 2013;310:804-11.
56. Jacobson IM, Ghalib R, Rodriguez- Torres M, Younossi Z, Corregidor A, Sulkowski MS, et al. SVR results of a once-daily regimen of simeprevir (SMV, TMC435) plus sofosbuvir (SOF, GS-7977) with or without ribavirin in cirrhotic and non-cirrhotic HCV genotype 1 treatment-naïve and prior null responder patients: The COSMOS study. Abstract LB-3. 64th Annual Meeting of the American Association for the Study of Liver Diseases. Washington, DC, 1-5 November 2013.
57. Sulkowski MS, Gardiner DF, Rodriguez- Torres M, Reddy KR, Hassanein T, Jacobson I, et al. Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. N Engl J Med 2014;370:211-21.
58. Zeuzem S, Kwo P, Chojkier M, Gitlin N, Puoti M, et al. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med 2014;370:1889-9.
59. Afdhal N, Reddy KR, Nelson DR, Lawitz E, Gordon SC, Schiff E, et al. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med 2014;370:1483-9.
60. Feld JJ, Kowdley KV, Coakley E, Sigal S, Nelson DR, Crawford D, et al. Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. N Engl J Med 2014;370:1594-603.
61. Zeuzem S, Jacobson IM, Baykal T, Marinho RT, Poordad F, Bourliere M, et al. Retreatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. N Engl J Med 2014;370:1604-14.
62. Ferenci P, Bernstein D, Lalezari J, Cohen D, Luo Y, Cooper C, et al. ABT- 450/r-ombitasvir and dasabuvir with or without ribavirin for HCV. N Engl J Med 2014;370:1983-9.
63. Poordad F, Hezode C, Trinh R, Kowdley KV, Zeuzem S, Agarwal K, et al. ABT- 450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis. N Engl J Med 2014;370:1973-82.
64. Lawitz E, Vierling J, Murillo A. High efficacy and safety of the all-oral combination regimen, MK-5172/MK-8742 +/- RBV for 12 weeks in HCV genotype 1 infected patients: The C-WORTHY study. Abstract 76. 64th Annual Meeting of the American Association for the Study of Liver Diseases, Washington, DC, 1-5 November 2013.
65. Gane EJ, Stedman CA, Hyland RH, Ding X, Svarovskaia E, Subramanian GM, et al. Efficacy of nucleotide polymerase inhibitor sofosbuvir plus the NS5A inhibitor ledipasvir or the NS5B non-nucleoside inhibitor GS-9669 against HCV genotype 1 infection. Gastroenterology 2014;146:736-43e1.
66. Kohli A, Sims Z, Nelson A, Osinusi A, Tefari G, Pang PS, et al. Combination oral, hepatitis c antiviral therapy for 6 or 12 weeks: final results of the SYNERGY trial. Abstract 27LB. 21st Conference on Retroviruses and Opportunistic Infections, Boston, 3-6 March 2014.
67. Lok AS, Gardiner DF, Hezode C, Lawitz EJ, Bourliere M, Everson GT, et al. Randomized trial of daclatasvir and asunaprevir with or without PegIFN/RBV for hepatitis C virus genotype 1 null responders. J Hepatol 2014;60:490-9.
68. Everson GT, Sims KD, Rodriguez- Torres M, Hezode C, Lawitz E, Bourliere M, et al. Efficacy of an interferon- And ribavirin-free regimen of daclatasvir, asunaprevir, and BMS-791325 in treatment-naive patients with HCV genotype 1 infection. Gastroenterology 2014;146:420-9.
69. Camma C, Petta S, Cabibbo G, Ruggeri M, Enea M, Bruno R, et al. Cost-effectiveness of boceprevir or telaprevir for previously treated patients with genotype 1 chronic hepatitis C. J Hepatol 2013;59:658-66.
70. Pollack A. FDA approves pill to treat hepatitis C. New York Times 2013. www.nytimes.com/2013/12/07/business/fda- Approves-pill- To- Treat-hepatitis-c. html.
71. Jaeckel E, Cornberg M, Wedemeyer H, Santantonio T, Mayer J, Zankel M, et al. Treatment of acute hepatitis C with interferon alfa-2b. N Engl J Med 2001;345:1452-7.
72. Piroth L, Larsen C, Binquet C, Alric L, Auperin I, Chaix ML, et al. Treatment of acute hepatitis C in human immunodeficiency virus-infected patients: The HEPAIG study. Hepatology 2010;52:1915-21.
73. Fierer DS, Dietrich DT, Mullen MP, Branch AD, Uriel AJ, Carriero DC, et al. Telaprevir in the treatment of acute hepatitis C virus infection in HIV-infected men. Clin Infect Dis 2014;58:873-9.
74. Forns X, Fontana RJ, Moonka D, McHutchinson JG, Symonds WT, Denning JM. Initial evaluation of the sofosbuvir compassionate use program for patients with severe recurrent HCV following liver transplantation. Abstract 1084. 64th Annual Meeting of the American Association for the Study of Liver Diseases, 1-5 November 2013, Washington, DC.
75. United Network for Organ Sharing. www.unos.org.
76. Wright TL, Donegan E, Hsu HH, Ferrell L, Lake JR, Kim M, et al. Recurrent and acquired hepatitis C viral infection in liver transplant recipients. Gastroenterology 1992;103:317-22.
77. Wang CS, Ko HH, Yoshida EM, Marra CA, Richardson K. Interferon-based combination anti-viral therapy for hepatitis C virus after liver transplantation: A review and quantitative analysis. Am J Transplant 2006;6:1586-99. (Pubitemid 43945798)
78. Pungpapong S, Aqel BA, Koning L, Murphy JL, Henry TM, Ryland KL, et al. Multicenter experience using telaprevir or boceprevir with peginterferon and ribavirin to treat hepatitis C genotype 1 after liver transplantation. Liver Transplant 2013;19:690-700.
79. Charlton MR, Gane E, Manns MP, Brown RS, Curry MP, Kwo PY, et al. Sofosbuvir and ribavirin for the treatment of established recurrent hepatitis C infection after liver transplantation: preliminary results of a prospective, multicenter study. Abstract LB-2. 64th Annual Meeting of the American Association for the Study of Liver Diseases, 1-5 November 2013, Washington, DC.
80. Curry MP, Afdhal NH, Forns X, Chung RT, Terrault NA. Pretransplant sofosbuvir and ribavirin to prevent recurrence of HCV infection after liver transplantation. Abstract 213. 64th Annual Meeting of the American Association for the Study of Liver Diseases, 1-5 November 2013, Washington, DC.
81. Kwo P, Mantry P, Coakley E, Te H, Vargas H, Brown R, et al. Results of the phase 2 study M12-999: interferon-free regimen of ABT-450/r/ABT-267 + ABT- 333 + ribavirin in liver transplant recipients with recurrent HCV genotype 1 infection. Abstract O114. 49th Annual Meeting of the European Association for the Study of the Liver, 9-13 April 2014, London, UK.
82. Sulkowski M, Pol S, Mallolas J, Fainboim H, Cooper C, Slim J, et al. Boceprevir versus placebo with pegylated interferon alfa-2b and ribavirin for treatment of hepatitis C virus genotype 1 in patients with HIV: A randomised, double-blind, controlled phase 2 trial. Lancet Infect Dis 2013;13:597-605.
83. Sulkowski MS, Sherman KE, Dieterich DT, Bsharat M, Mahnke L, Rockstroh JK, et al. Combination therapy with telaprevir for chronic hepatitis C virus genotype 1 infection in patients with HIV: A randomized trial. Ann Intern Med 2013;159:86-96.
84. Dietrich D, Rockstroh J, Orkin C, Gutierrez F, Klein MB, Reynes J, et al. Simeprevir (TMC435) plus peginterferon/ribavirin in patients co-infected with HCV genotype-1 and HIV-1: primary analysis of the C212 study. Abstract PS9/5. 14th European AIDS Conference (EACS 2013), 2013, Brussels.
85. Rockstroh J, Nelson M, Soriano V, Arasteh K, Gua J. STARTVerso 4 phase III trial of faldaprevir plus peg interferon alfa-2a and ribavirin (PR) in patients with HIV and HCV genotype 1 coinfection: end of treatment response. Abstract 1099. 64th Annual Meeting of the American Association for the Study of Liver Diseases, 1-5 November 2013, Washington, DC.
86. Rodriguez- Torres M, Rodriguez-Orengo J, Gaggar A, Symonds W, McHutchison J, Gonzalez M. Sofosbuvir and peginterferon alfa-2a/ribavirin for treatment-naïve genotype 1-4 HCV-infected patients who are coinfected with HIV. Abstract 714. ID Week, San Francisco, 2-6 October 2013.
87. Sulkowski MS, Rodriguez- Torres M, Lalezari JP. All-oral therapy with sofosbuvir plus ribavirin for the treatment of HCV genotype 1, 2, and 3 infection in patients co-infected with HIV (PHOTON-1). Abstract 212. The 64th Annual Meeting of the American Association for the Study of Liver Diseases, 1-5 November 2013, Washington, DC.
88. Ford N, Kirby C, Singh K, Mills EJ, Cooke G, Kamarulzaman A, et al. Chronic hepatitis C treatment outcomes in low- And middle-income countries: A systematic review and meta- Analysis. Bull World Health Organ 2012;90:540-50.
89. Ford N, Singh K, Cooke GS, Mills EJ, von Schoen- Angerer T, Kamarulzaman A, et al. Expanding access to treatment for hepatitis C in resource-limited settings: lessons from HIV/AIDS. Clin Infect Dis 2012;54:1465-72.
90. Datta PJ. Gilead, local generic players in talks to bring hepatitis C drug into India. The Hindu 2014. www.thehindubusinessline.com/companies/gilead- local-generic-players-in- Talks- To-bring-hepatitis-c-drug-into-india/ article5649841.ece.